A retrospective study evaluating prognostic value of neutrophil to lymphocyte ratio in patients with stage IV non-small cell lung cancer receiving first line therapy of pembrolizumab monotherapy or in combination with chemotherapy

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 09 Mar 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Carboplatin; Pemetrexed
Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
Focus Therapeutic Use

Most Recent Events

09 Mar 2021 New trial record
31 Jan 2021 Results assessing prognostic value of neutrophil to lymphocyte ratio and PD-L1 expression in patients with metastatic non-small cell lung cancer treated with first line therapy, either pembrolizumab monotherapy or pembrolizumab in combination with carboplatin or pemetrexed, presented at the 2020 World Conference on Lung Cancer.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight